CEBPB and cancer: Consistent with lucicebtide activity on C/EBPβ target genes in cancer cells (18), ID2, BIRC3, CyclinA2 and CDK1 were significantly downregulated in lucicebtide-treated M2-cells (Supplementary Figure S3C).